India’s Top 10 Powerful Influential Pharma Leaders 2016 List.Pricing, Regulatory Hurdles & OTC Market remain the key focus at Pharma Leaders 2016 Research Report. Dilip Shanghvi, Pankaj Patel, Samprada Singh, R.C.Juneja,Dilip Surana are among top 10 Powerful Indian Pharma Leaders 2016.
Prof Ramesh Mishra*
Indian Pharmaceutical Industry has evolved as a dominant & powerful sector since india’s seventy years of independence & yet the industry remains largely fragmented with top 100 players in complete command of dominance. Today these top 100 companies have more than 80 % of the market share out of which majority players are domestic companies. MNC’s in india has grown significantly but their growth of late has been outpaced by the aggressive Indian companies. Pharma Leaders, India’s first media to interview more than 500 leaders of the pharmaceutical industry has brought out this special report titled “India’s Top 10 Powerful Pharma Leaders 2016” based on a credible research inputs followed by interviewing & interacting with all the stakeholders of the pharmaceutical industry. The key findings of the report other than the selection of the top 10 Leaders are as the following.
Using comprehensive interview, survey, and observational data from 100 successful Pharma Leaders using the competitive market analysis, the researchers found that our findings on the top 10 influential Powerful Pharma Leaders of 2016 — defined as aggressiveness, assertiveness, and confidence — were also able to “excel in tough conditions considered very risky”.
- Indian Players are likely to dominate the market till 2025
- Top 100 Domestic Players may join hands together through co-marketing, R&D & brand acquisitions.
- Top privately held companies will go for public (IPO) in next 2 years, till 2018
- Top Brands will be up for grabs with premium
- Generics will be the key drivers for growth
- Top 100 companies will set up manufacturing facilities to fuel growth engines.
- Second generation Leaders will take over the Leadership Mantles.
- OTC segments will be the part of top 40 companies out of 100.
- Field Force of top 30 Companies will double by 2018.
- Exports will be the key focus.
India’s Top 10 Powerful Pharma Leaders 2016
There are many organizations who are involved in rankings based purely on turnovers or profits or purely on financial background. While Pharma Leaders research desk purely respects the mechanism of selection process & the judging criteria, we have given considerable emphasis on the trust & branding factors & the credible face of the leadership steering the company’s growth engine & putting patients first. In this feature survey, we have only taken the Indian companies & not included the MNC’s as the scope of the study research involved included the role of visionary leadership, team buildings, brand buildings, CSR & Indian perspective of looking leadership. Network 7 Media Group, the research wing of Pharma Leaders undertook the responsibilities of finding the top 10 Powerful Pharma Leaders of 2016.
The primary objective that our experts looked at is Brand Equity & Leadership Dominance. Indian pharma market is dominated by a strong patronage of brands by the different stakeholders; the research paper looked into great details as how the person concerned has been able to influence the society & industry at large. Corporate Social Responsibilities (CSR) also was one of the top focus while determining the leadership role of the top 10 influential Pharma Leaders of 2016.
Selection Process & Methodology
Unlike other organizations, Pharma Leaders being a media house relied purely on the external patronage & opinions of the key stakeholders on determining the top 10 Leaders.The sample size of the analysis included all 29 states & 7 Union territories, both urban & rural areas on a pan india basis. More than 5000 opinion makers were consulted which included the followings.
- Contemporary Peers
- Past Leadership
- Distribution Agents
- Policy Makers
- Govt Agencies
- Image Consultants
- Medical Representatives
- Market Research Analysts
The Top 10 List
- Dilip Shanghvi,MD,Sun Pharmaceutical Industries Ltd
- Desh Bandhu Gupta, Chairman, Lupin Limited
- Kallam Satish Reddy,Chairman,Dr. Reddy’s Laboratories Ltd
- Y.K. Hamied,Non-Executive Chairman,Cipla Ltd
- Pankaj R. Patel,Chairman & Managing Director,Zydus Cadila
- Glenn Saldanha, CMD, Glenmark Pharmaceuticals Ltd
- Samprada Singh, Chairman Emeritus,Alkem Labs Ltd
- Dilip Surana, CMD, Microlabs Ltd
- R.C.Juneja, Chairman, Mankind Pharma Ltd
- Habil. F.Khorakiwal, Chairman, WockhardtLtd
Mr. Dilip Shanghvi,MD,Sun Pharmaceutical Industries Ltd
The current market capitalisation of Sun Pharma stands at Rs 184,441.59crore.
Mr. Dilip Shantilal Shanghvi founded Sun Pharmaceutical Industries Limited in 1982 and served as its Managing Director since May 29, 2012. Mr. Shanghvi served as the Chairman and Managing Director of Sun Pharmaceutical Industries, Inc. He has been the Chairman and Managing Director of Sun Pharma Advanced Research Company Limited since March 1, 2012. He has wide extensive industrial experience in the Pharmaceutical industry. He has been the Chairman of Taro Pharmaceutical Industries Ltd., since July 18, 2013. Mr. Shanghvi has been the Chairman of Caraco Pharmaceutical Laboratories Ltd. since 1997. Mr. Shanghvi served as the Chairman of the Board of Sun Pharmaceutical Industries Ltd until May 28, 2012. since 1999. He served as the Chairman of the Board of Taro Pharmaceutical Industries Ltd. from September 20, 2010 to April 18, 2012. He has been a Director of Sun Pharma Advanced Research Company Limited since March 1, 2006. He serves as a Director at Sun Speciality Chemicals Pvt. Ltd., Sun Resins & Polymers Pvt. Ltd., Sun Fastfin Services Pvt. Ltd., Sun Petrochemicals Private Limited, SPARC Bio-Research Private Limited, Sun Pharma Global Inc., British Virgin Island, Sun Pharma De Mexico SA DE CV, SPIL De Mexico SA DE CV and Shantilal Shanghvi Foundation. He serves as its Promoter Executive Director of Sun Pharmaceutical Industries Ltd .He served as a Director of Taro Pharmaceutical Industries Ltd. until April 18, 2012. Mr. Shanghvi is graduate in commerce from Kolkata University.
Sun Pharmaceutical Industries Limited, a specialty generic pharmaceutical company, manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, such as psychiatry, anti-infectives, neurology, cardiology, orthopaedic, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental, and nutritionals. It also provides APIs for anti-cancers, peptides, steroids, sex hormones, and controlled substances, as well as over-the-counter products. The company was founded in 1983 and is based in Mumbai, India
Dr Desh Bandhu Gupta, Chairman, Lupin Limited
The current market capitalisation of Lupin stands at Rs 67,437.26 crore.
Dr. Desh Bandhu Gupta is Chairman at Lupin Ltd. He is on the Board of Directors at Zyma Laboratories Ltd., Rahas Investments Ltd., Visiomed Investments Pvt. Ltd., Lupin Holdings Pvt. Ltd., Lupin Investments Pvt Ltd., Lupin International Pvt Ltd., Polynova Industries Ltd., Lupin Properties Ltd., Novamed Investments Pvt. Ltd., and Synchem Investments Pvt. Ltd.Mr. Gupta was previously employed as an Associate Professor by Birla Institute of Technology & Science. In 1968 at 30 years of age, Desh Bandhu Gupta started off with was a very ambitious dream of manufacturing drugs of national priority. The aim was to fight life threatening diseases with a business capital of 5000 Indian Rupees that he borrowed from his wife. He started his working career as Associate Professor at Birla Institute of Sciences and Technology, but never seemed satisfied with his contributions to the country and society. With an initial investment coming his way in the form of loan from the Central Bank, he set up the manufacturing unit in Mumbai and attained this uphill task he had set of first year; Sales target of 5 lakh Indian Rupees.
Lupin Limited, a pharmaceutical company, develops, manufactures, and markets a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in India and internationally. It offers formulations for use in the areas of cardiology, central nervous system (CNS), diabetes, anti-asthma, gastro- intestinal, COPD, and gynecology; and APIs for use in therapeutic areas of cephalosporins, cardiovascular, and anti-TB. The company also develops drug delivery technologies; and biosimilars for various therapeutic indications, such as oncology, anti-inflammatory, anti-virals, rheumatoid arthritis, endocrinology, diabetes, ophthalmology, and women’s health. In addition, it engages in the novel drug discovery and development programs for use in the treatment of CNS disorders, oncology, immunology, pain and inflammation, and metabolic disorders. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is based in Mumbai, India.
Mr. Kallam Satish Reddy,Chairman,Dr. Reddy’s Laboratories Ltd
The current market capitalisation of Dr. Reddy’s Labs stands at Rs 54,502.30crore.
Mr. Kallam Satish Reddy, B.Tech., M.S., serves as a Member at Management Council at Dr. Reddy’s Laboratories Ltd. Mr. Reddy served as the Managing Director of Dr. Reddy’s Laboratories Ltd. and has been its Chairman since May 13, 2014. Mr. Reddy served as Executive Director in charge of the manufacturing operations of active pharmaceutical ingredients and formulations, research and development activities and new product development at Dr. Reddy’s Laboratories Ltd. since 1993 and served as its Chief Operating Officer. He served as Vice Chairman of Dr. Reddy’s Laboratories Ltd. from March 30, 2013 to May 13, 2014. He has been a Whole Time Director at Dr. Reddy’s Laboratories Ltd. since January 18, 1993, Director of Diana Hotels Limited as well as certain of Dr. Reddys Laboratories Ltd.’s subsidiaries. and also served as Director at Dr. Reddy’s Laboratories Ltd. He served as Director of Cheminor, and is a member of the Indian Institute of Chemical Engineers. Mr. Reddy has a Master of Science degree in Medicinal Chemistry from Purdue University in 1990 and a Bachelor of Technology degree in Chemical Engineering from Osmania University in 1988.
Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment also engages in biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients (APIs) and intermediates, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations and new chemical entities (NCEs) for dermatology and neurology therapeutic areas. It also engages in the discovery, development, and commercialization of novel small molecule agents in therapeutic areas, such as metabolic disorders, and pain and inflammation; and has a portfolio of in-licensed patented dermatology products. As of March 31, 2016, this segment had 19 active products in development programs pipeline that are in various stages of development. The company’s therapeutic categories primarily include gastro-intestinal, cardiovascular, pain management, oncology, dermatology, urology, and nephrology. It has strategic partnership with GlaxoSmithKline plc to develop and market products outside India; collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology; and collaboration agreements with Merck Serono and Amgen. Dr. Reddy’s Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.
Dr. Y.K. Hamied,Non-Executive Chairman,Cipla Ltd
The current market capitalisation stands at Rs 48,590.40crore.
Dr. Yusuf Khwaja Hamied, also known as YK, served Managing Director of Cipla Limited from August 1, 2008 to March 31, 2013. Dr. Hamied joined the Cipla Limited as an officer-in-charge of research and development in 1960. He is well-respected for his vast and varied experience of 48 years not only in India but also internationally. He has done research work under Lord Todd FCS, a Nobel Laureate. He is a highly qualified and Eminent Chemist. He has been the Chairman at Cipla Limited since April 1, 2013. He serves as Non-Executive Non Independent Director at Cipla Limited. He obtained a Doctorate in chemistry from Cambridge University.
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India. It offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as women’s health, cardiovascular, children’s health, dermatology and cosmeceuticals, diabetes, HIV-AIDS, hepatitis, oncology, infectious diseases and critical care, malaria, neurosciences, ophthalmology, osteoporosis, respiratory, and urology. The company also provides veterinary products, including anti-infectives, anti-inflammatories, anti-thyroids, immunosuppressants, parasiticides, nutraceuticals, and feed additives for various animals, including companion, equine, livestock, poultry, swine, and aqua products. In addition, it offers inhaled medication and devices comprising dry powder inhalers, metered-dose inhalers, nasal sprays, nebulizers, and inhalation accessory devices, as well as spacers and related devices; and personal products. The company also exports its products to Africa, the Middle East, Latin America, the Asia Pacific, China, Russia, and internationally. Cipla Limited was founded in 1935 and is based in Mumbai, India.
Mr.Pankaj R. Patel,Chairman & Managing Director,Zydus Cadila
The current market capitalisation of Cadila Healthcare stands at Rs 40,248.44 crore.
Mr. Pankaj R. Patel, M.Pharm, serves as the Chairman of Cadila Healthcare Limited and has been its Managing Director since September 1, 2006. Mr. Patel serves as the Chairman and Managing Director of Zydus Animal Health Limited, a subsidiary of Cadila Healthcare Limited and he is the guiding force behind its fast tracked growth. He has been Senior Vice President at Federation of Indian Chambers of Commerce and Industry since December 2015. He serves as the Regional Representative to the South East Asia Region of WHO. He over 35 years of professional experience and spearheads the affairs of Zydus Cadila. He served as the Non Executive Chairman of Zydus Wellness Limited from August 2009 to July 14, 2014. He serves as a Non-Executive Independent Director of Nirma Limited. He has been an Independent Non-Executive Director of Torrent Power Limited since September 29, 2006 and Cadila Healthcare Limited since August 15, 1995. He served as a Non Executive Director of Cipla Limited from March 5, 2008 to September 2014. He served as a Director of Zydus Wellness Limited from April 27, 2009 to July 14, 2014. He served as a Director of Dialforhealth India Limited, Zydus Pharmaceuticals Limited, BAAP Diagnostics Limited, Zydus Technologies Limited, Vadilal Chemicals Limited and Kafnavati Club Limited. He served as a Director of Onconova Therapeutics, Inc. He served as a Director at Gujarat Themis Biosyn Ltd. from January 15, 1992 to October 25, 2008. He served as Additional Director of Nirma Limited since October 28, 2006. He has been the President of Gujarat Chamber of Commerce & Industry since 2006. He is involved in many charitable activities including as a Trustee of Shri. B.V. Patel Pharmaceutical Education and Research Development Center in India. He is associated with various associations like Federation of Indian Chamber of Commerce & Industry, Indian Drug Manufacturers Association, Indian Pharmaceutical Alliance, Basic Chemicals, Pharmaceuticals and Cosmetics Export Promotion Council (CHEMEXIL) etc. He is actively involved in various institutions and serves on the advisory committees and academic councils of leading pharmaceutical colleges and management institutes. He has published over 50 research papers. For his innovative business practices, he was conferred with the award “Pharma Man of the Year” by the Federation of Indian Industry and Economists in 2004. The World Pharmaceutical Frontiers’ in their global raking of the most influent people in the filed of healthcare had featured Mr. Patel in their ‘First Pharma 40’ list. He is one of the most successful and highly respected Pharma entrepreneurs in India. He has a Masters in Pharmaceuticals and Pharmaceutical Technology. He is a Science graduate of Bombay University. He is a Law graduate from the Bombay University.
Cadila Healthcare Limited engages in the research, development, production, marketing, and distribution of pharmaceutical products. Its product portfolio includes active pharmaceutical ingredients and human formulations. The company offers branded formulations in the therapeutic areas of neurological, neutraceutical, pain management, gastro intestinal, respiratory, anti-infective, biological, cardiovascular, female healthcare, dermatology, and others. It also provides consumer wellness products, such as Sugar Free, a low calorie sugar substitute; EverYuth, a range of skincare products; and Nutralite, a cholesterol free table spread. In addition, the company is developing a pipeline of 20 biologics comprising 14 biosimilars and 6 novel biological products; and new drugs in cardio-metabolic disorder, inflammation, pain, and oncology therapeutic areas. Further, it provides animal healthcare products. Additionally, the company is developing vaccines that are designed to address infectious diseases, including next-generation influenza, measles-mumps-rubella-varicella, typhoid, DPT-HiB, hepatitis-B, hepatitis-A, hepatitis-E, Japanese encephalitis, Leishmaniasis, Malaria, Haemorrhagic Congo Fever, Ebola, HPV, and combination vaccines. Cadila Healthcare Limited was founded in 1952 and is based in Ahmedabad, India.
Mr. Glenn Saldanha, CMD, Glenmark Pharmaceuticals Ltd
The current market capitalisation of Glenmark stands at Rs 26,152.76 crore.
Mr. Glenn Mario Saldanha has been the Managing Director and Chief Executive Officer of Glenmark Pharmaceuticals Ltd. since 2001. Mr. Saldanha serves as the Chief Executive Officer of Glenmark Pharmaceuticals S.A. He has worked for Eli Lilly in the U.S and was a Management Consultant with Price Waterhouse Coopers. His Services have been used by Smithkline Beecham, Rhone Poulenc Rhorer, Astra, Merck and Johnson and Johnson, among others. He has 15 years of experience in Pharmaceutical Industry. He has been the Chairman of Glenmark Pharmaceuticals Ltd. since May 10, 2011. Mr. Saldanha served as Chairman of Glenmark Generics Ltd. He has been a Director of Glenmark Pharmaceuticals S.A. since 1998. He served as Independent Director of Talwalkars Better Value Fitness Ltd. since October 2009 until November 22, 2011. He was awarded the Watumall Foundation Award for overall excellence. Mr. Saldanha holds a B.Pharm. from Bombay University and an MBA from New York University’s Leonard N.Stern School of Business (US).
Glenmark Pharmaceuticals S.A operates as a pharmaceutical research and development company. It engages in clinical and non-clinical development of the group’s new chemical entity programs. The company’s products include Oglemilast, a PDE-4 inhibitor for asthma; GRC 8200, a DPP-4 inhibitor for diabetes; GBR 401, an anti-CD19 monoclonal antibody; CB-1 antagonist for obesity; and GBR 500, a therapeutic monoclonal antibody for chronic autoimmune disorders. The company has a strategic global collaboration with Sanofi. The company was founded in 2004 and is based in Neuchâtel, Switzerland. Glenmark Pharmaceuticals S.A operates as a subsidiary of Glenmark Pharmaceuticals, Ltd.
Mr. Samprada Singh, Chairman Emeritus,Alkem Labs Ltd
The current market capitalization of Alkem stands at Rs 21,927.62crore.
Mr. Samprada Singh founded Alkem Laboratories Limited in August 8, 1973 and has been its Chairman Emeritus since April 1, 2015. Mr. Singh served as the Chairman of Alkem Laboratories Ltd. Mr. Singh is one of the most respected and successful entrepreneurs of the Indian Pharmaceutical Industry. The growth of Alkem and the success of Mr. Singh is most amazing since Mr. Singh started this organization from scratch and through tremendous dynamism, vision and leadership has brought it to the top of the Indian Pharmaceutical Industry today. To Mr. Singh goes the major credit of seeing Alkem through its various stages of progress from the beginning, till today, when Alkem is a name to reckon with in the Indian Pharmaceutical Industry. In 1953, Mr. Singh made a small beginning as a Retail Chemist. In 1960, he started a business of Pharmaceutical distribution in Patna under the banner of ‘Magadh Pharma’. Due to his sincerity, hard work and affable nature, Mr. Singh was able to acquire the distributorship of several renowned multinationals and soon, successfully built up a sound distribution network in the eastern region of India. Realizing the limitations of expanding in the distribution business, in the year 1972, Mr. Singh became the founder Director of a Bombay based Pharmaceutical company. Mr. Singh selected healthcare and pharmaceuticals as his focus area as an entrepreneur. From the very early days of Alkem Laboratories Ltd., Mr. Singh always emphasized the need for excellence in products, personnel, quality and service. He has been a Non Executive Director of Alkem Laboratories Limited since August 08, 1973. In the year 2004, Mr. Singh was honoured with the prestigious “Life Time Contribution Award” by the Express Pharma Excellence Awards, which is reckoned by many as the Oscar of the Indian Pharmaceutical Industry. In June 2002, Mr. Singh received yet another award. The ‘Medicine Update Lifetime Achievement – Health Care Award’ went onto honour his achievement in the pharmaceutical industry as one of it’s most successful entrepreneurs. In October 2000, Mr. Singh was conferred upon with the ‘Life Time Achievement Award’ by Pharma Business and Technology, one of the most distinguished and respected entrepreneurs of the Indian Pharmaceutical industry. During Mr. Singh four years as an undergraduate, Mr. Singh exhibited his dynamism through various student activities. Mr. Singh entered Gaya College, Patna University in 1946 to specialize in Commerce. He received a B.Com. Degree from Patna University in 1950. Mr. Singh holds a post graduate degree in Political Science.
Alkem Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells pharmaceutical and neutraceutical products. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and neutraceuticals in acute and chronic therapeutic areas, such as anti-infective, gastro-intestinal, pain and analgesics, vitamins/minerals/nutrients, cardiac and diabetology, gynecology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants. It offers its products to various hospitals, government institutions, and medical institutions through a network of 7,000 stockiest in India and internationally. Alkem Laboratories Limited was founded in 1973 and is headquartered in Mumbai, India.
Mr. Dilip Surana, CMD, Microlabs Ltd
Privately held Company
Mr. Dilip Surana son of Late Shri G. C. Surana (Founder of Micro Labs Limited) joined the family business in 1985 at a young age of 21 years, and rapidly absorbed the nuances of Corporate Management that grew the company rapidly into a global pharmaceutical enterprise specializing in life saving medicines. His early years in industry were marked by distinguished accomplishments and thus steering Micro Labs among the top ranking companies in the pharma sector. The AWACS ranking for the company has improved from over 100 in 1985 to 18 as on 2014. Under his leadership, the company established world-class state-of-the-art research and manufacturing facilities covering Active Pharmaceutical Ingredients (APIs) and finished dosage forms as well as infrastructure for new drug discovery. He instilled the most stringent quality standards in his pharmaceutical enterprise. As a result, Micro Labs has to its credit, all the international regulatory approvals including US FDA, UK MHRA, Australian TGA etc., reflecting the high standards of quality and regulatory compliance of research and manufacturing facilities. He pioneered the concept of specialty – wise focused divisions in the Indian Pharmaceutical Industry and established various divisions that cater to special therapeutic segments in chronic disease management. He is a regular participant in various international seminars and summits relating to Pharma industry. He is instrumental in inducting Senior Pharma veterans in the company, to bring in the much needed professionalism in the company. Recognizing the dynamism and contribution of Mr. Dilip Surana to the Pharmaceutical Industry, he has been honored as the ‘Dynamic Entrepreneur of the year 2010’, honoured as the ‘Great Son of karnataka’ by Governor of Karnataka his excellency HR Bhardwaj in 2011, honoured as ‘Most Dynamic Entrepreneur of the Year’ 2013 and ‘Entrepreneur of the year’ 2014.
Micro Labs Ltd. manufactures pharmaceutical products. It offers products ranging from oral solids and liquids, topicals to injectables in pediatric, gynecology, ophthalmology, gastro, orthopedic, nephrology, neuro psychiatry, dermatology, diabetology, general surgery, ENT, dental, neurology, cardio diabetic, dyslipidemias, hypertension, metabolic syndrome, arrhythmias, and veterinary areas. The company markets branded generics through own and outsourced distribution networks in India and internationally. Micro Labs Ltd. was founded in 1973 and is based in Bengaluru, India. It has subsidiaries and representative offices in the United Kingdom, the Russian Federation, Vietnam, Ukraine, and Mexico. The company has manufacturing plants in Hosur, Bengaluru, Pondicherry, Goa, Baddi, and Sikkim, India; and the United Kingdom, Canada, and South Africa.
Mr.R.C.Juneja, Chairman, Mankind Pharma Ltd
Privately held Company
Mr R. C. Juneja, the founder of Mankind Group, is one of the most reputed business leaders in the pharmaceutical industry. He laid the foundation stone of Mankind Pharma in 1986, and the company became a legal entity in 1991. Mankind Group earned its reputation as a fully integrated pharmaceutical company in 1995. In 2011, Mr. Juneja was presented with the ‘India Business Icon (Pharma) Award’ by Network 18.He firmly believes that honesty and transparency go hand-in-hand with business acumen. He also shares his life experiences with the youth and encourages them to come forward and take up new challenges and responsibilities. He revolutionized the Indian pharmaceutical market by inspiring others to follow the trend of providing quality products at an economical price.
Mankind Pharma Limited manufactures pharmaceutical products for antibiotic, antifungal, NSAIDs, gastrointestinal, anthelmintic, cardiovascular, dermal, erectile dysfunction, and other categories. It also offers contraceptive products, over-the-counter medicines, pregnancy detection cards, artificial sweeteners, and other products; and nutritional supplements, cosmetics, anti-infective tablets, anti-diabetic tablets, proton pump inhibitors, anti-allergic tablets, emergency contraceptives, anti-emetic, and other products. In addition, the company provides active pharmaceutical ingredients for various therapeutic areas, such as cardiology, respiratory, neurology, gastroenterology, diabetology, dermatology, ophthalmology, gynecology, and others. It sells its products through a network of stockists, CFAs and CSAs, chemists and medical stores, and doctors. Mankind Pharma Limited was incorporated in 1991 and is headquartered in New Delhi, India. It has operations in Asia, Africa, South-East Asia, and Gulf countries.
Mr. Habil. F.Khorakiwal, Chairman, WockhardtLtd
The current market capitalisation of Wockhardt stands at Rs 10,060.98crore
Dr. Habil F. Khorakiwala founded Wockhardt Ltd. in 1967 and serves as its Executive Chairman. Dr. Khorakiwala has bee Group Chief Executive Officer at Wockhardt Ltd. since 1967. Dr. Khorakiwala served as the Managing Director of Wockhardt Ltd. until April 2009. Dr. Khorakiwala serves as the Chairman at Wockhardt USA, Inc., and Wockhardt Hospitals Ltd. He serves as the Chairman of Khorakiwala Holdings and Investments Private Limited. He serves as Chairman of Wockhardt Bio AG. He serves as Director of Dartmour Holdings Private Limited. He has been a Director at Wockhardt Hospitals Limited since August 28, 1991. He serves as a Director of Wockhardt Bio AG, Wockhardt Europe Limited and CP Pharmaceuticals Limited. He is an Ex-President of Indian Pharmaceutical Alliance (IPA). He served as a Director of SOFTBPO Global Services Ltd. since August 1, 2006. Dr. Khorakiwala served as an Independent Director of IDream Film Infrastructure Company Ltd from October 26, 2005 to January 28, 2014. He serves as a Vice-President of FICCI and a member of the National Manufacturing Competitiveness Council. Dr. Khorakiwala was the recipient of the Ernst & Young `Entrepreneur of the Year’ Award in 2004 in the category of Healthcare and Life Sciences. He holds Bachelor’s Degree in Pharmacy from Purdue University. Dr. Khorakiwala holds an Master Degree in Pharmaceutical Science from the Purdue University, USA and is an alumnus of the Harvard Business School, USA.
Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs), and vaccines in India, the United States, Europe, and other countries. It provides pharmaceutical products in the therapeutic areas of anti-infectives, cardiology, dermatology, diabetology, neurology, pain management, respiratory, and other areas. The company offers generic products that comprise injectables, including cephalosporins and non-cephalosporins; and value-added generics. Its biopharmaceutical products include Glaritus, an insulin analog; Wosulin, which is r-DNA insulin; Wepox, a recombinant erythropoietin is used in the treatment of anaemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine. The company also provides contract manufacturing and packaging services for sterile injectables, lyophilisation, solid dose, liquids/ointments/creams, sachets and powders, and specialized products; API manufacturing services; and contract research services. It develops various molecules primarily in the area of anti-infectives, which include WCK 771 that is in Phase II human clinical trials for the treatment of staphylococcal infections; and WCK 2349, WCK 4873, and WCK 4086 lead molecules, which are under pre-clinical trials. The company was incorporated in 1999 and is headquartered in Mumbai, India. Wockhardt Limited is a subsidiary of Themisto Trustee Company Private Limited.
The Author Prof Mishra is Executive Editor of Pharma Leaders.